Trial Profile
A Phase I, Open Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Properties of Orally Administered AT-406 in Patients With Advanced Solid Tumours and Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Xevinapant (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Ascenta Therapeutics; Debiopharm
- 30 Sep 2023 Results published in the Clinical Pharmacology and Therapeutics
- 02 Jun 2015 Interim results in 16 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 21 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.